Bicuspid Aortic Valve (BAV)
Conditions
Keywords
Bicuspid Aortic Valve, Dilated ascending aorta, Aortic regurgitation, Aortic stenosis, Acoustic cardiography
Brief summary
Pervious studies indicated that the prevalence of bicuspid aortic valve（BAV） might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.
Detailed description
There is no recognized comprehensive epidemiological data on congenital BAV in China, although findings of BAV is common in clinical practice. In the course of the Venus-A registry clinical study, which was the first Aortic Valve Replacement (TAVR) trial in China, the investigators concluded about 40% of the final enrollment of BAV patients. Since then, an increasing number of scholars have figured out that the prevalence of BAV may be much higher in China than abroad. This study was designed to investigate Gene backgrounds, pathological progress, imaging characteristics of young health BAV participants and their relationships in long-term follow-up. These findings may help to identify high risk individuals with specific gene expression or other features in clinical observation.
Interventions
None listed
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* The patients were aged 14-60 years; * Definitive diagnosis of BAV by imaging (echocardiography, aortic CTA, cardiac magnetic resonance, etc.) * Patients were informed about the nature of the study and agreed to participate in all the terms of the study and signed an informed consent form approved by the ethics committee.
Exclusion criteria
* Poor patient compliance and inability to complete follow-up visits as required; * Rheumatic heart valve disease, other organic valve disease. * Hyperthyroidism, severe anemia, and other factors that significantly affect hemodynamics. * Other circumstances that the researcher believes should be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SAVR / TAVR | 5 year | Indications for surgical or transcatheter aortic valve replacement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular events(MACE) | 5 year | Ascending aortic aneurysm or aortic dissection, all-cause death, cardiac death, non-fatal stroke, hospitalization for heart failure |
Other
| Measure | Time frame | Description |
|---|---|---|
| Synchronized analysis of phonocardiogram and electrocardiogram | 6 or 12 month depending on severity of valves | Synchronized PCG and ECG data using a wearable cardiac monitoring patch |
| Echocardiography | 6 or 12 month depending on severity of valves | Valve morphology, Degree of valve stenosis or regurgitation, Degree of widening of the ascending aorta, Left ventricular ejection fraction(LVEF) changes, Degree of left ventricular hypertrophy or enlargement. |
Countries
China
Contacts
Primary ContactWenli Zhang, MD
Outcome results
None listed